Core Muscle Size Predicts Postoperative Outcome in Lung Transplant Candidates

Weig, Thomas; Milger, Katrin; Langhans, Bettina; Janitza, Silke; Sisic, Alma; Kenn, Klaus; Irlbeck, Thomas; Pomschar, Andreas; Johnson, Thorsten; Irlbeck, Michael; Behr, Jürgen; Czerner, Stephan; Schramm, René; Winter, Hauke; Neurohr, Claus; Frey, Lorenz; Kneidinger, Nikolaus

doi:10.1016/j.athoracsur.2015.10.041

Cited by 67 publications

(88 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic susceptibility, comorbidities, physiological aging, and environmental factors, also play a role in the pathophysiology of frailty. [7][8][9][10][11] Sarcopenia and frailty share similar underlying mechanisms, such as physical inactivity, chronic inflammation, and endocrine dysregulation. 2 Biomarkers for frailty have been suggested, based on the concept that aging represents a low-grade chronic inflammatory process, sometimes termed "inflammaging."…”

Section: Pathophys Iology Of Fr Ailt Ymentioning

confidence: 99%

“…2 Biomarkers for frailty have been suggested, based on the concept that aging represents a low-grade chronic inflammatory process, sometimes termed "inflammaging." 13 Sarcopenia, like frailty, may be a risk factor for worse outcomes in lung transplant candidates; however, data are conflicting, with some studies showing lower pretransplant skeletal muscle mass measured radiographically being a risk factor for worse outcomes, 9,14 and others showing risk for longer hospital stays but not mortality. [3][4][5] Sarcopenia (loss of skeletal muscle mass) may be a precursor to the development of frailty and its adverse health outcomes.…”

Section: Pathophys Iology Of Fr Ailt Ymentioning

confidence: 99%

See 1 more Smart Citation

Report from the American Society of Transplantation on frailty in solid organ transplantation

Kobashigawa

Dadhania

Bhorade

et al. 2019

American Journal of Transplantation

187

185

View full text Add to dashboard Cite

chronic kidney disease; CST, Canadian Society of Transplantation; CT, computed tomography; DASI, Duke activity status index; DEXA, dual energy X-ray absorptiometry; ESRD, end-stage renal disease; FFP, fried frailty phenotype; HR, hazard ratio; HRQO, health-related quality of life; MCSD, mechanical circulatory support device; MELDNa, model for end-stage liver disease and sodium; MRI, magnetic resonance imaging; SPPB, short physical performance battery.

show abstract

Section: Pathophys Iology Of Fr Ailt Ymentioning

confidence: 99%

Section: Pathophys Iology Of Fr Ailt Ymentioning

confidence: 99%

Report from the American Society of Transplantation on frailty in solid organ transplantation

Kobashigawa

Dadhania

Bhorade

et al. 2019

American Journal of Transplantation

187

185

View full text Add to dashboard Cite

show abstract

“…Therefore, in nonobese waitlisted ILD patients, reducing body fat mass by nutritional intervention cannot be recommended because it may instead decrease TTR and albumin and possibly promote sarcopenia, 30,31 which results in poor prognosis. The relationship between body fat mass and TTR has not been reported in ILD.…”

Section: Discussionmentioning

confidence: 99%

Nutrition‐related factors associated with waiting list mortality in patients with interstitial lung disease: A retrospective cohort study

Oshima

Nishimura

Chen‐Yoshikawa

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

Japanese patients with interstitial lung disease (ILD) sometimes die waiting for lung transplantation (LTx) because it takes about 2 years to receive it in Japan. We evaluated nutrition‐related factors associated with waiting list mortality. Seventy‐six ILD patients were hospitalized in Kyoto University Hospital at registration for LTx from 2013 to 2015. Among them, 40 patients were included and analyzed. Patient background was as follows: female, 30%; age, 50.3 ± 6.9 years; body mass index, 21.1 ± 4.0 kg/m2; 6‐minute walk distance (6MWD), 356 ± 172 m; serum albumin, 3.8 ± 0.4 g/dL; serum transthyretin (TTR), 25.3 ± 7.5 mg/dL; and C‐reactive protein, 0.5 ± 0.5 mg/dL. Median observational period was 497 (range 97‐1015) days, and median survival time was 550 (95% CI 414‐686) days. Survival rate was 47.5%, and mortality rate was 38.7/100 person‐years. Cox analyses showed that TTR (HR 0.791, 95% CI 0.633‐0.988) and 6MWD (HR 0.795, 95% CI 0.674‐0.938) were independently correlated with mortality and were influenced by body fat mass and leg skeletal muscle mass, respectively. It is suggested that nutritional markers and exercise capacity are important prognostic markers in waitlisted patients, but further study is needed to determine whether nutritional intervention or exercise can change outcomes.

show abstract

“…Our results further support the usefulness of PR even in patients with end-stage lung disease. This is of particular interest for patients awaiting lung transplantation, since pretransplant functional status is closely related to transplant outcome [3]. Large studies of the UNOS database have shown that pretransplant 6MWD is a significant predictor of waitlist mortality [26] and is significantly associated with posttransplant survival [27, 28].…”

Section: Discussionmentioning

confidence: 99%

“…Interest in the benefits of PR in patients with end-stage lung disease awaiting lung transplantation is increasing, since maintenance of exercise capacity and muscle mass are critical for survival on the waiting list and for transplant outcome [3-5]. …”

Section: Introductionmentioning

confidence: 99%

Impact of Nocturnal Noninvasive Ventilation on Pulmonary Rehabilitation in Patients with End-Stage Lung Disease Awaiting Lung Transplantation

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Pulmonary rehabilitation (PR) in patients awaiting lung transplantation is crucial to ensure a transplant benefit. However, PR in patients with end-stage lung disease treated with noninvasive ventilation (NIV) remains an area of uncertainty. Objectives: The aim of the study was to assess the potential benefit of PR in patients awaiting lung transplantation treated with NIV. Methods: Patients awaiting lung transplantation who underwent comprehensive inpatient PR from 1998 to 2015 were retrospectively analyzed. Success of PR was assessed by comparing admission and discharge. Multivariate regression models were applied to assess the impact of long-term nocturnal NIV on PR success. Results: In total, 1,044 patients were included in the analysis. Thereof, 296 patients (28%) were treated with NIV. PR in patients treated with NIV resulted in a significant increase in 6-min walk distance (6MWD; from 250 ± 117 to 309 ± 116 m; p < 0.0001) and in various items of the Short Form Health Survey (SF)-36 questionnaire. The increase in 6MWD was higher in patients treated with NIV than in patients without NIV (59 ± 63 vs. 48 ± 55 m; p = 0.003). Furthermore, improvements of various lung function variables were higher in patients with NIV. Finally, multivariate generalized regression analysis revealed that NIV therapy was associated with improvement of 6MWD (p = 0.023) while controlling for various baseline characteristics. Conclusions: PR in patients with end-stage lung disease awaiting lung transplantation on nocturnal NIV is feasible and is associated with improvements of exercise capacity and quality of life. Furthermore, despite more advanced lung disease, patients treated with NIV have an increased benefit of PR compared to patients without NIV while awaiting lung transplantation.

show abstract

Core Muscle Size Predicts Postoperative Outcome in Lung Transplant Candidates

Cited by 67 publications

References 28 publications

Report from the American Society of Transplantation on frailty in solid organ transplantation

Report from the American Society of Transplantation on frailty in solid organ transplantation

Nutrition‐related factors associated with waiting list mortality in patients with interstitial lung disease: A retrospective cohort study

Impact of Nocturnal Noninvasive Ventilation on Pulmonary Rehabilitation in Patients with End-Stage Lung Disease Awaiting Lung Transplantation

Contact Info

Product

Resources

About